In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Variants derived from actriib and uses therefor

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

Ppar active compounds

Coumpounds, compositions and methods for modulating the activity of nuclear receptors are provided In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors In certain embodiments, the compounds are N-substituted pyridones

Modulators of lxr

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Compounds for the treatment of metabolic disorders

Compounds of the invention are disclosed, such as compounds of formulae LX - LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

LXR and FXR Modulators

Described herein is the use of a compound represented by Formula IA or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a condition in a mammalian subject, the condition being gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, or tumor-lysis syndrome: (see formula IA)

Compounds and method for reducing uric acid

Compound for the treatment of metabolic disorders

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions in-cluding gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyper-uricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syn-drome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is 0, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hy-droxy, alkoxy having 1 or 2 carbon atoms, fluoro. chloro, bromo, and amino. A is phenyl unsubstituted or substituted by one, two or three groups selected from the group consisting of halo, alkyl having 1 or 2 carbon atoms. perfluoromethyL alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring atoms wherein the cycloalky! is unsubstituted or one one two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heleraromatic ring having 1 or 2 ring heteroatoms selected from N. S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound by a ring carbon.

Shalini Sharma

Papers

Compounds for the treatment of metabolic disorders

Compounds and method for reducing uric acid

Compound for the treatment of metabolic disorders

Tetrazole compounds for reducing uric acid

Method for the treatment of metabolic disorders